16 September 2026 editorial review · Trial
Control-IQ pivotal trial (iDCL): t:slim X2 closed-loop vs. sensor-augmented pump: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: No new discrepancy identified in the reviewed summary, stated design, primary endpoint and eligibility against the available registry. This is a bounded protocol comparison, not confirmation of efficacy.
Registry: NCT03563313. Registered endpoint checked: Time in Target Range (26 weeks). Eligibility check: Registry age 14 Years to not specified; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Accessible primary literature: Outcomes in Pump- and CGM-Baseline Use Subgroups in the International Diabetes Closed-Loop Trial.; Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.. Limits: Primary abstract findings were available; supplementary tables and full adverse-event adjudication were not comprehensively re-reviewed. Registry eligibility is not a claim of current site availability.